This inventor holds 1 USPTO granted patent. Top assignee: Genesen Co., Ltd.. Active years: 2022.
Company Filing History:
Years Active: 2022
Title: Hyuk Kwon Kwon: Innovator in TLR Inhibition
Introduction
Hyuk Kwon Kwon is a notable inventor based in Pyeongtaek, South Korea. He has made significant contributions to the field of pharmaceutical compositions, particularly in the area of toll-like receptor (TLR) inhibition. His work focuses on developing innovative solutions for diseases mediated by TLR pathways.
Latest Patents
Hyuk Kwon Kwon holds a patent for a fusion polypeptide that inhibits TLR1/2, TLR2/6, TLR7, TLR8, and TLR9 signaling pathways, as well as Toll-like receptor 4 (TLR4) and TLR3. The patent, titled "Peptide for toll-like receptor (TLR) inhibition and pharmaceutical composition comprising same," describes a pharmaceutical composition that can prevent or treat various TLR pathway-mediated diseases. This invention has shown excellent efficacy in inhibiting TLR4 and various TLR pathways, making it a promising candidate for addressing autoimmune diseases, inflammatory diseases, and degenerative neurological diseases.
Career Highlights
Hyuk Kwon Kwon is associated with Genesen Co., Ltd., where he continues to advance his research and development efforts. His innovative approach to TLR inhibition has positioned him as a key figure in the pharmaceutical industry.
Collaborations
He collaborates with talented individuals such as Sang Dun Choi and Hyeon Jun Shin, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Hyuk Kwon Kwon's work in TLR inhibition represents a significant advancement in the field of pharmaceuticals. His contributions have the potential to lead to new treatments for various diseases, showcasing the importance of innovation in healthcare.